For informational purposes only — not investment advice

← Back to signals

INBX

Inhibrx Biosciences, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
10.0d↓-1.3%
as of 2026-10-30 · shares short vs 2026-09-30

Fund 13D/13G Filings (3)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Viking GlobalSC 13G/A−78K9.3%
+1.5% vs SPY
-0.7% abs
2026-08-14↗
Viking GlobalSC 13G/A—10.0%
-16.2% vs SPY
-10.7% abs
2026-05-15↗
Viking GlobalSC 13G/A—10.0%—2026-02-17↗

Tracked Funds Holding (2)

FundManagerShares HeldPosition Value
Viking GlobalAndreas Halvorsen1.1M$111M
Point72Steve Cohen17K$2M

Quarter-end 13F positions for the tracked funds holding this stock.